
Frontiers in Science Lead Article
Published on 07 Oct 2025
Frontiers in Science Lead Article
Published on 07 Oct 2025
Join Prof Masanori Aikawa (Brigham and Women's Hospital, USA) and colleagues for a complimentary virtual symposium on next steps for precision cardiovascular medicine.
Prof Valentin Fuster, Prof Filip K. Swirski, and Dr Girish Nadkarni (Mount Sinai Health System, USA) -- The future of cardiovascular medicine lies in integrating population-based and precision interventions that reduce global disease burden.
Dr Siyeon Rhee and Prof Joseph C. Wu (Stanford University, USA) -- Precision cardiovascular medicine requires leveraging patient variability as an opportunity, not an obstacle, while embedding equity in both data collection and clinical implementation.
Prof Rainer Schulz (Justus-Liebig University Giessen, Germany) -- Stronger basic and translational science—including improved disease models, identification of cellular therapeutic targets, and safer delivery methods—is vital for the success of precision cardiovascular medicine.
Prof Hugo ten Cate (Maastricht University, the Netherlands) -- Deep patient risk profiling can enable precision medicine approaches that safely match next-generation antithrombotic treatments to the right patients.
Prof Amam Mbakwem (World Heart Federation, Nigeria) -- Cardiovascular health for all demands national action plans that integrate precision approaches based on globally representative research—enabled by leadership committed to equitable access and context-relevant implementation (coming soon).
Heterogeneity in the complex pathobiology and presentation of cardiovascular diseases (CVDs)—the leading cause of death globally—limits the effectiveness of conventional “one-size-fits-all” therapies.
Integrative systems approaches, which involve unbiased omics analyses (especially proteomics and single-cell analyses), bioinformatics, and network science, now offer the potential for a precision medicine innovation paradigm to tackle CVDs.
Artificial intelligence is driving new opportunities in patient profiling and computational precision drug design and development.
Various RNA therapeutics in development offer promise for effective precision therapy and could help address conventional drug development obstacles, such as cost and time.
Interdisciplinary and intersectoral collaboration throughout the research and innovation pathway, underpinned by global health policy leadership, is necessary to implement a precision cardiovascular medicine paradigm.
A summary of the lead article in a Q&A format, with infographics and a video.
A version of the lead article written for—and peer reviewed by—kids aged 8-15 years.
Follow the science, follow Frontiers in Science